US7776838 — Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Method of Use · Assigned to Wellstat Therapeutics Corp · Expires 2027-08-17 · 1y remaining
What this patent protects
This patent protects methods for treating and preventing toxicity caused by chemotherapeutic and antiviral agents using acylated pyrimidine nucleosides.
USPTO Abstract
The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1791 |
— | uridine-triacetate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.